Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vactosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 known ✓ | P36897 | 20/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 18/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | TGFB1 | P01137 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vactosertib SCHEMBL29508696 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL29493095 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL250076 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL248684 | 0.94 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL26345807 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL30568127 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL248262 | 0.91 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL19492123 | 0.91 | TGFBR1 (0.83) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL249547 | 0.90 | TGFBR1 (0.81) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL249408 | 0.90 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 863 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104985-A1 | TGF-BETA RECEPTOR INHIBITORS FOR USE IN THE THERAPEUTIC TREATMENT OF A PULMONARY FIBROTIC DISEASE | A.D.A. S.R.L. (IT) | 2026-05-21 | — | — | WO | claimed |
| CN-122038274-A | Method for inducing differentiation and maturation of alveolar organoids and application thereof | 广州国家实验室 | 2026-05-15 | — | — | CN | claimed |
| CN-122038284-A | Method for inducing differentiation of anterior foregut endoderm cells to form lung progenitor cells and application thereof | 广州国家实验室 | 2026-05-15 | — | — | CN | claimed |
| US-20260132380-A1 | Hepatocyte Expansion Methods | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-05-14 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108496-A1 | METHODS FOR REPROGRAMING EXHAUSTED T CELLS AND BOOSTING IMMUNE CHECKPOINT BLOCKADE THERAPY FOR CANCER | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-23 | — | — | US | claimed |
| US-20260092257-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2026-04-02 | — | — | US | claimed |
| EP-4676954-A1 | TGF-BETA INHIBITORS FOR USE FOR TREATING RESISTANT OR UNRESPONSIVE CANCER IN PATIENTS | Scholar Rock, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4678739-A1 | IN VITRO METHOD FOR OBTAINING CORTICAL BRAIN ORGANOIDS, CORTICAL BRAIN ORGANOIDS AND USES THEREOF | Fundación Pública Andaluza Progreso Y Salud (ES) | 2026-01-14 | — | — | EP | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| EP-3973963-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3972990-A1 | GENERATING DORSAL FOREGUT, AND ANTERIOR DOMAIN, ENDODERM CELLS | The Cleveland Clinic Foundation (US) | 2022-03-30 | — | — | EP | claimed |
| EP-3973964-A1 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3969570-A1 | METHODS FOR OBTAINING EYE FIELD PROGENITOR CELLS FROM HUMAN PLURIPOTENT STEM CELLS | Novo Nordisk A/S (DK) | 2022-03-23 | — | — | EP | claimed |
| US-11279915-B2 | Methods, compositions, and kits for producing beige adipocytes and treating metabolic disorders | MAINE MEDICAL CENTER RESEARCH INSTITUTE (US) | 2022-03-22 | — | — | US | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| CN-114096557-A | Generation of germ layer cells in the dorsal foregut and anterior structural domains | 克利夫兰诊所基金会 | 2022-02-25 | — | — | CN | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| CN-114072163-A | New material for healing skin wound and preventing scar | 芝加哥大学 | 2022-02-18 | — | — | CN | claimed |
| WO-2022022624-A1 | METHOD FOR PRODUCING CARDIOMYOCYTES BY MEANS OF REPROGRAMMING | 南京昕瑞再生医药科技有限公司 | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108496-A1 | METHODS FOR REPROGRAMING EXHAUSTED T CELLS AND BOOSTING IMMUNE CHECKPOINT BLOCKADE THERAPY FOR CANCER | BMP4, CD274, WNT3A | TGFBR1 5/4885MAPK14 1797/4885RIPK2 289/4885 |
| US-20260092257-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC PROGENITOR CELLS | FLT4, CSF3R, FGFR3 | TGFBR1 712/4885MAPK14 1293/4885RIPK2 3174/4885 |
| US-20260132380-A1 | Hepatocyte Expansion Methods | HGF, CTNND1, MET | TGFBR1 36/4885MAPK14 192/4885RIPK2 530/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | TGFBR1 91/4885MAPK14 162/4885RIPK2 817/4885 |
| US-11279915-B2 | Methods, compositions, and kits for producing beige adipocytes and treating metabolic disorders | FABP4, LIPC, PNLIP | TGFBR1 4858/4885MAPK14 4529/4885RIPK2 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.